France-headed advanced biofuels and biochemical process developer Global Bioenergies has announced that it has received its first order from global oil, gas, and energy major Shell plc, to provide volumes of bio-based isobutene derivatives for performance assessment.
An error occurred
On your profile you can see what subscriptions you have access to and more information.
Is some of the information wrong – please contact our customer service.
Please reload the page
Do you want to read the whole article?
- Six editions per year
- Full access to all digital content
- The E-magazine Bioenergy international
- And more ...
Global Bioenergies has focused its strategy on the bioproduction of isobutene as this molecule is one of the main building blocks in the world of chemistry.
Its derivatives can be used in a wide range of sectors from cosmetics and fine chemicals to commodities and fuels.
The global market for isobutene is approximately 15 million tonnes annually.
Shell plans to explore the possibility of replacing current hydrocarbon-based isobutene and its derivatives with their equivalents from renewable sources while maintaining the same level of performance.
Global Bioenergies brings ready-to-use solutions to industrialists in numerous areas. Such a switch to renewable isobutene could, in the future, allow for up to 70 percent less carbon dioxide (CO2) emissions compared to the hydrocarbon-based equivalent.
Shell has ordered testing volumes of two bio-isobutene derivatives from Global Bioenergies, and both will be manufactured and delivered in the coming weeks.
The first focus of our Pomacle production unit is to commercialize renewable isododecane in the field of cosmetics. But this unit can also serve other markets, and several prospects from various fields recently asked us for bio-isobutene and derivatives, commented Marc Delcourt, Co-Founder and CEO of Global Bioenergies.
